Efficacia e tollerabilità del methotrexate nel trattamento dell'artrite reumatoide

Clinica Terapeutica

Volumn 149, Issue 2, 1998, Pages 109-114

  Pappalardo, A ^a,b   Salli L ^a   Compagno, M ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b c/o Clin Ortopedica Policlin P G ^*  (Italy)

Author keywords

Efficacy; Methotrexate; Rheumatoid arthritis; Tolerability

Indexed keywords

METHOTREXATE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN;

ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ADULT; AGED; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; POLYMERASE CHAIN REACTION; REMISSION;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; TREATMENT OUTCOME;

EID: 0031595336     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Harris ED: The rationale for combination therapy of rheumatoid arthritis based on Pathophysiology. J Rheumatol 23: 2-4, 1996 (suppl 44)
2. Pipitone V, Lapadula G, Pipitone N: Moderni orientamenti nella terapia dell'artrite reumatoide. Reumatismo 46:21-25, 1994
3. Leroux JL, Damon M, Chavis C, et al.: Effects of a single dose of methotrexate on 5-and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 19:863-866, 1992
4. Sperling RI, Benincaso AI, Anderson RJ, et al.: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35:376-384, 1992
5. O'Callahan P, Forrest MJ, Brooks PM: Inhibition of neutrophil chemotaxis in methotrexate treated rheumatoid arthritis patients. Rheumatol Int 8:41-45, 1988
6. Laurindo IM, Mello SB, Cossermelli W: Influence of low doses of methotrexate on Superoxide anion production by polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Rheumatol 22:633-638, 1995
7. Olsen NJ, Murray LM: Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 32:378-385, 1989
8. Nakajima A, Hakoda M, Yamanaka H, et al.: Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann Rheum Dis 55:237-242, 1996
9. Chang DM, Weinblatt ME, Schur PH : The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 19:1678-82, 1992
10. Barrera P, Boerbooms AM, van de Putte LB, et al.: Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 25:234-253, 1996
11. Wascher TC, Hermann J, Brezinschek R, et al.: Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 24: 73-75, 1994
12. Aaron SL: Augmentation of IL-2 secretion by methotrexate therapy of rheumatoid arthritis. Arthritis Rheum 32: S50, 1989
13. Polisson RP, Dooley MA, Dawson DV: Interleukin-2receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 37: 50-56, 1994
14. Crilly A, McInness IB, McDonald AG, et al.: Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 22: 224-226, 1995
15. Weinblatt ME, Coblyn JS, Fox DA, et al.: Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818-822, 1985
16. Weinblatt ME: Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol 35: 403-406, 1996
17. Furst DE, Erikson N, Clute L: Adverse experience with methotrexate during 176 week of a long term prospective trial in patients with rheumatoid arthritis. J Rheumatol 17: 1628-1635, 1990
18. Kerstens PJSM, Boerbooms AMT, Jeurissen MEC: Accelerated nodulosis during low-dose methotrexate in rheumatoid arthritis. An analysis of ten cases. J Rheumatol 19: 867, 1992
19. Hilliquin P, Renoux M, Perrot S, et al.: Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol, 35: 441-445, 1996
20. Gutierrez-Ureña S, Molina JF, Garcia CO, et al.: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39: 272-276, 1996
21. Phillips CA, Cera PJ, Mangan TF: Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 19: 229, 1992
22. Seideman P, Muller-Suur R, Ekman E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 20: 1126-1128, 1993
23. Boerbooms AM, Kerstens PJ, van Loenhout JW, et al.: Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24(6): 411-421, 1995
24. Wernick R, Smith DL: Central nervous system toxicity associated with weekly low dose methotrexate treatment. Arthritis Rheum 32: 770-775, 1989
25. Zonneveld IM, Bakker WK, Dijkstra PF, et al.: Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 132: 184-187, 1996
26. Moder KG, Tefferi A, Cohen MD, et al.: Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99(3): 276-281, 1995
27. Finger DR, Klipple GL: Gynecomastia following low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 22(4): 796-797, 1995